Orion Pharma (OP) is a part of Orion Group, the leading health-care company in Finland, which develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The core therapy areas of OP’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which OP develops inhaled Easyhaler® pulmonary drugs. All of OP’s manufacturing plants and most of its R&D operations are in Finland, and the headquarters are in Espoo, Finland. OP‘s pharmaceutical innovations are created within its R&D organization, and the focus is on early-phase drug development.
Main tasks in the project
- WP2 – Orion will contribute by providing expertise in clinical development in Parkinson’s Disease.
- WP3 – Orion will contribute by providing expertise in use of biosensors in Parkinson’s disease patients.
- WP7 – Orion will contribute by providing expertise in AI and statistical analyses.
